Results 1 to 10 of about 9,091 (151)

HPV16 E6 seropositivity among cancer-free men with oral, anal or genital HPV16 infection

Papillomavirus Research (Amsterdam, Netherlands), 2016
Antibodies against the Human papillomavirus 16 (HPV16) E6 oncoprotein appear years prior to clinical diagnosis of anal and oropharyngeal cancer, but whether they develop around the time of HPV infection is unclear.
Daniel C Beachler, Tim Waterboer, Christine M Pierce Campbell   +2 more
exaly   +6 more sources

HPV16 infection decreases vaccine-induced HPV16 antibody avidity: the CVT trial [PDF]

npj Vaccines, 2022
The HPV vaccine has shown sustained efficacy and consistent stabilization of antibody levels, even after a single dose. We defined the HPV16-VLP antibody avidity patterns over 11 years among women who received one- or three doses of the bivalent HPV ...
Sabrina H. Tsang, John T. Schiller, Carolina Porras, Troy J. Kemp, Rolando Herrero, John Schussler, Monica S. Sierra, Bernal Cortes, Allan Hildesheim, Douglas R. Lowy, Ana Cecilia Rodríguez, Byron Romero, Nicolas Çuburu, Jaimie Z. Shing, Ligia A. Pinto, Joshua N. Sampson, Aimée R. Kreimer, on behalf of the Costa Rica HPV Vaccine Trial Group   +17 more
doaj   +6 more sources

Acetylation of intragenic histones on HPV16 correlates with enhanced HPV16 gene expression

Virology, 2015
We report that many histone modifications are unevenly distributed over the HPV16 genome in cervical cancer cells as well as in HPV16-immortalized keratinocytes. For example, H3K36me3 and H3K9Ac that are common in highly expressed cellular genes and over exons, were more common in the early than in the late region of the HPV16 genome.
Cecilia Johansson, Haoran Yu, Stefan Schwartz   +2 more
exaly   +5 more sources

Redetection of Cervical Human Papillomavirus Type 16 (HPV16) in Women With a History of HPV16 [PDF]

Journal of Infectious Diseases, 2013
The purpose of this study was to examine the rate of and risks for cervical human papillomavirus type 16 (HPV16) redetection in women with documented or suspected HPV16 infection.A convenience sample of women aged 13-21 years were seen at 4-month intervals for HPV DNA testing and cytology. Serum samples were obtained at baseline and annually.A total of
Anna-Barbara Moscicki, Sepideh Farhat, TERESA M Darragh   +2 more
exaly   +8 more sources

Anti-HPV16 Antibody Titers Prior to an Incident Cervical HPV16/31 Infection [PDF]

Viruses, 2021
The goal of this study was to investigate the serological titers of circulating antibodies against human papillomavirus (HPV) type 16 (anti-HPV16) prior to the detection of an incident HPV16 or HPV31 infection amongst vaccinated participants. Patients were selected from a prospective post-HPV vaccine longitudinal cohort at Mount Sinai Adolescent Health
Ana Gradissimo, Viswanathan Shankar, Fanua Wiek, Lauren St. Peter, Yevgeniy Studentsov, Anne Nucci-Sack, Angela Diaz, Sarah Pickering, Nicolas F. Schlecht, Robert D. Burk   +9 more
openaire   +4 more sources

Oral HPV16 Prevalence in Oral Potentially Malignant Disorders and Oral Cavity Cancers

Biomolecules, 2020
The role of human papillomavirus type 16 (HPV16) in oral potentially malignant disorders (OPMD) and oral cavity carcinoma (OC) is still under debate.
Kai Dun Tang, Lilian Menezes, Kurt Baeten, Laurence J. Walsh, Bernard C. S. Whitfield, Martin D. Batstone, Liz Kenny, Ian H. Frazer, Gert C. Scheper, Chamindie Punyadeera   +9 more
doaj   +2 more sources

HPV16 E5 is produced from an HPV16 early mRNA spliced from SD226 to SA3358

Virus Research, 2018
The HPV16 E5 open reading frame (ORF) is present on the majority of all alternatively spliced HPV16 mRNAs, but it is currently unknown how well it is translated into E5 protein. To identify HPV16 mRNAs that are efficiently translated into E5, we have generated cDNA plasmids expressing individual, alternatively spliced HPV16 mRNAs with the potential to ...
Kersti, Nilsson, Christopher, Norberg, Ann-Kristin, Mossberg, Stefan, Schwartz   +3 more
core   +4 more sources

HPV16 Seropositivity and Subsequent HPV16 Infection Risk in a Naturally Infected Population: Comparison of Serological Assays [PDF]

PLoS ONE, 2013
Several serological assays have been developed to detect antibodies elicited against infections with oncogenic human papillomavirus (HPV) type 16. The association between antibody levels measured by various assays and subsequent HPV infection risk may differ.
Shih-Wen Lin, Arpita Ghosh, Carolina Porras, Sarah C Markt, Ana Cecilia Rodriguez, Mark Schiffman, Sholom Wacholder, Troy J Kemp, Ligia A Pinto, Paula Gonzalez, Nicolas Wentzensen, Mark T Esser, Katie Matys, Ariane Meuree, Wim Quint, Leen-Jan van Doorn, Rolando Herrero, Allan Hildesheim, Mahboobeh Safaeian, Costa Rican Vaccine Trial Group   +19 more
openaire   +7 more sources

Efficient production of HPV16 E2 protein from HPV16 late mRNAs spliced from SD880 to SA2709

Virus Research, 2020
Human papillomaviruses (HPVs) produce a large number of alternatively spliced mRNAs, including a number of differently spliced mRNAs with the potential to produce E2 protein.
Yunji Zheng, Kersti Nilsson, Haoran Yu   +2 more
exaly   +2 more sources

Prevalence and Risk Assessment of Human Papillomavirus Infection in a Bengali Cohort

Journal of Pure and Applied Microbiology, 2023
Cervical cancer is a notable cause of mortality and morbidity among women of reproductive age. Human papillomavirus (HPV) is the leading cause of cervical cancer among women. Among 170 types of HPV; HPV-16 and -18 are responsible for cervical cancer. The
Nabamita Chaudhury, Tanusri Biswas, Koushik Bose, Prabir Sengupta, Arghya Nath, Nivedita Mukherjee, Anupam Basu, Subhra Kanti Mukhopadhyay   +7 more
doaj   +1 more source